Ilika eyes first orders as solid-state battery rollout gathers pace

Ilika reported H1 revenue of £0.6m (down from £1.0m a year earlier) and an EBITDA loss of £3.2m (versus a £1.9m loss prior), ending the period with £6.9m cash after a £4.2m raise. The company secured its first commercial Stereax electrode order from Cirtec Medical, has 21 customers evaluating Stereax and 27 assessing its Goliath EV/appliance cells, and has shipped a 10Ah Goliath prototype that it says could cut battery pack cost by ~£2,500 and reduce weight by 20%. Ilika is targeting follow-on orders this year, aims for a minimum viable Goliath product in 2026, and has received a £1.25m DRIVE35 grant with strategic backing from Jaguar Land Rover and the University of Oxford.

Analysis

Market structure: Ilika’s milestones primarily benefit niche medical-device OEMs, defence and appliance OEMs evaluating compact solid-state cells and early-stage suppliers (Cirtec Medical). Incumbent large-format Li-ion suppliers (LGES, CATL, SK On) are insulated near-term; meaningful share shift requires Goliath scaled to multi-Ah, mass-production by 2028–2030. Supply/demand signals are early: increased developer interest (Stereax customers 21 → follow-ons, Goliath evaluators +29% to 27) implies growing OEM pipeline but negligible near-term raw-material demand impact; commodity price effects are likely immaterial for 12–24 months.

Risk assessment: Key tails are technology-scaling failure, safety/regulatory rejection, or financing shortfall — cash £6.9m vs implied ~£6–7m annualized burn suggests a material funding event within 6–12 months. Near-term catalysts: follow-on Stereax orders (H1–H2 2026) and Goliath MVP feedback (through 2026); a missed order or negative cell test could halve valuation quickly. Hidden dependencies include manufacturing partner scale-up (Cirtec) and supplier qualification cycles at OEMs that add 6–18 months of delay.

Trade implications: For liquid portfolios, treat IKA as a capped binary long with 12–24 month horizon tied to MVP and order flow; size small (1–3% NAV). Use long-dated call structures or buy-and-hedge (shares + 12-month 30% OTM puts) to limit downside while keeping upside to product-adoption news. Cross-sector rotation: favor medtech device names (MDT, BSX) and defence suppliers exposed to lightweight power solutions; avoid increasing exposure to mid-tier lithium miners unless conviction of multi-year demand growth remains intact.

Contrarian angles: Consensus underestimates funding cadence risk and overestimates near-term commercialisation — market likely underprices a successful MVP but also underestimates dilution risk from future raises. Historical parallels: small solid-state developers often deliver prototypes but struggle at gigafactory scale (several years delay); therefore upside is binary and path-dependent. Unintended consequence: early positive demos can force aggressive fundraising and equity dilution, compressing short-term returns despite eventual tech success.

Key Decisions for Investors

• Establish a tactical long position in Ilika (AIM:IKA or OTCQX:ILIKF) sized 1.5–3.0% of NAV as a binary play on 2026 MVP and follow-on Stereax orders; horizon 12–24 months, take-profit at +200–300% or on confirmed multi-customer commercial orders, stop-loss at -50% or if cash falls below £3.2m.
• If options liquidity permits, buy 12–18 month call spread on IKA (buy ATM LEAP, sell ~+50% OTM) sized to 1% NAV to cap premium spend and capture upside to MVP milestones; if illiquid, buy shares and simultaneously purchase 12-month 30% OTM puts for downside protection.
• Implement a 12–36 month pair trade: long 1–2% NAV in defensive medtech leaders (Medtronic MDT or Boston Scientific BSX) to capture Stereax adoption potential, funded by a 1–2% NAV trim/short of commodity-sensitive lithium miners (Albemarle ALB or Lithium Americas LAC) to hedge against long-term disruption/demand shifts.
• Set hard monitoring triggers: require confirmation of at least one follow-on commercial Stereax order by Q3 2026 and positive 10Ah Goliath cell qualification data by H2 2026; if either fails, reduce IKA position to <0.5% and reassess exposure to avoid dilution or technical-de-risk failures.